Promore Pharma AB (publ)
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PROMO.ST research report →
Companywww.promorepharma.com
Promore Pharma AB (publ), a biopharmaceutical company, develops peptide-based drug candidates in Sweden and internationally. Its product candidates include PXL01 that is in Phase IIa study for the prevention of post-surgical adhesions and scars, and for the prevention of dermal scars, as well as for tendon repair surgery in the hand; and LL-37, which is in Phase IIb clinical studies for treating patients with venous leg ulcers, stimulate the healing of chronic wounds, and for the treatment of diabetic foot ulcers. It entered into a cooperation agreement with Fidia Farmaceutici S.
- CEO
- Jonas Ekblom
- IPO
- 2017
- Employees
- 1
- HQ
- Solna, SE
Price Chart
Valuation
- Market Cap
- $293.55M
- P/E
- -0.25
- P/S
- 2965.12
- P/B
- 0.48
- EV/EBITDA
- -10.39
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -16005.05%
- Op Margin
- -26871.72%
- Net Margin
- -26887.88%
- ROE
- -97.51%
- ROIC
- -180.95%
Growth & Income
- Revenue
- $99.00K · -76.26%
- Net Income
- $-26,619,000 · 1.27%
- EPS
- $-0.44 · 22.81%
- Op Income
- $-26,603,000
- FCF YoY
- -9.83%
Performance & Tape
- 52W High
- $2.00
- 52W Low
- $0.04
- 50D MA
- $0.12
- 200D MA
- $0.17
- Beta
- 1.51
- Avg Volume
- 2.06M
Get TickerSpark's AI analysis on PROMO.ST
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our PROMO.ST Coverage
We haven't published any research on PROMO.ST yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate PROMO.ST Report →